A record of what Sumeet Bagadia said publicly, with the source. Not advice.
“Recommends buying Sun Pharmaceutical Industries at ₹1,699, targeting ₹1,850 with a stop loss at ₹1,620. The stock is in an overall uptrend, consolidating near its demand zone, with a sustained move above ₹1,730 expected to confirm a reversal and renewed upward trajectory in the short to medium term.”
Sumeet Bagadia’s track record (trackable calls only): 1528 graded calls · 95% CI 32–37%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
Entry: ₹1,699, as stated.
Target ₹1,850, stop ₹1,620, as stated.
Window: 90 days, from the call's own horizon word ("in the short to medium term").
The stop ₹1,620 was reached on a close before the target ₹1,850. Miss.
The grader’s working: R3 TRADE_SETUP: entered ₹1699 on 2025-07-28 (stated entry ₹1699, LEVEL_CMP entry, filled); stop ₹1620 breached at close ₹1595.2 on 2025-08-06. Window 90 days — rule H4: the quote says "in the short to medium term" (short-term 30 days, medium-term 90, long-term 12 months).
How it played out
How this is worked out- Target or stop first
- The stop was reached on a close before the target was.
- Time to target
- The target was not reached on a close inside the window.
- Worst close against it
- The closing price went as far as 6.11% against the call up to 6 Aug 2025, when the call was decided, measured from the entry price. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.